Ulrich Blaschke, PhD CureVac

Ulrich Blaschke is VP of Technical Development at CureVac AG, a company focusing on mRNA as medicinal products. In this position, he is responsible for drug substance and drug product process development, development of analytical methods as well as advancing the mRNA technology for production of mRNA at industrial scale.

Furthermore, he is interested in the specific aspects of mRNA manufacturing and controls within the evolving global regulatory framework for this new class of therapeutic molecules.

Before entering the mRNA area, Ulrich was working for different pharmaceutical companies as Cinfa Biotech, Boehringer Ingelheim and Stada Arzneimittel in Germany and in the US.

For 15 years, he worked on all aspects of biosimilars development with a strong focus on CMC.

Ulrich studied chemistry and biochemistry at the Westfälische-Wilhelms University in Münster, Germany. After his PhD studies, he joined Rockefeller University, New York as a postdoctoral fellow working in the field of synthetic protein chemistry.